Joshua James Milligan

Mr. Joshua James Milligan

Duke University, Durham, California, USA
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2017 in Science Immunology
Verified
Journal Article
Closed access
PDF file
YYYanqi Ye
Yanqi Ye
CWChao Wang
Chao Wang
XZXudong Zhang
Xudong Zhang
QHQuanyin Hu
Quanyin Hu
YZYuqi Zhang
Yuqi Zhang
ZGZhen Gu
Zhen Gu
Transdermal microneedle patch integrated with whole tumor lysate containing melanin facilitates cancer immunotherapy upon near-infrared light irradiation.

29 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JMJoshua James Milligan
Joshua James Milligan
SSSoumen Saha
Soumen Saha
Nanomedicines represent the cutting edge of today’s cancer therapeutics. Seminal research decades ago has begun to pay dividends in the clinic, allowing for the delivery of cancer drugs with enhanced systemic circulation while also minimizing off-target toxicity. Despite the advantages of delivering cancer drugs using nanoparticles, micelles, or other nanostructures, only a small fraction of the injected dose reaches the tumor, creating a narrow therapeutic window for an otherwise potent drug. First-pass metabolism of nanoparticles by the reticuloendothelial system (RES) has been identified as a major culprit for the depletion of nanoparticles in circulation before they reach the tumor site. To overcome this, new strategies, materials, and functionalization with stealth polymers have been developed to improve nanoparticle circulation and uptake at the tumor site. This review summarizes the strategies undertaken to evade RES uptake of nanomedicines and improve the passive and active targeting of nanoparticle drugs to solid tumors. We also outline the limitations of current strategies and the future directions we believe will be explored to yield significant benefits to patients and make nanomedicine a promising treatment modality for cancer.

3 June 2021 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
IJIrene C. Jenkins
Irene C. Jenkins
JMJoshua James Milligan
Joshua James Milligan
ACAshutosh Chilkoti
Ashutosh Chilkoti

1 April 2022 in Current Opinion in Biotechnology
Verified
Journal Article
Closed access
JMJoshua James Milligan
Joshua James Milligan
SSSoumen Saha
Soumen Saha
IJIrene C Jenkins
Irene C Jenkins
ACAshutosh Chilkoti
Ashutosh Chilkoti

19 October 2022 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
JSJeffrey L. Schaal
Jeffrey L. Schaal
JBJayanta Bhattacharyya
Jayanta Bhattacharyya
JBJeremy Brownstein
Jeremy Brownstein
KSKyle C. Strickland
Kyle C. Strickland
GKGarrett Kelly
Garrett Kelly
ACAshutosh Chilkoti
Ashutosh Chilkoti

6 July 2025 in Advanced Science
Verified
Journal Article
Open access
JMJoshua James Milligan
Joshua James Milligan
RSRachel L. Strader
Rachel L. Strader
ACArunangshu Chakrabarty
Arunangshu Chakrabarty
MNMax Ney
Max Ney
PSParul Sirohi
Parul Sirohi
ACAshutosh Chilkoti
Ashutosh Chilkoti
Biomaterials can improve cancer immunotherapies by controlling their release and thereby optimizing their time‐dependent engagement of the immune system. In this study, an approach is described to control the release of a potent immunostimulant—CpG oligodeoxynucleotide—from a genetically‐encoded elastin‐like polypeptide (ELP) depot. A CpG‐binding ELP containing an oligolysine domain (ELP‐Lys 12 ) is synthesized that electrostatically complexes CpG and formulate it with an excipient ELP. The ELP‐CpG complex retains the thermally responsive phase behavior of the parent ELP, transitioning into a viscous depot at body temperature. Stepwise addition of excipient ELP predictably changes ELP‐CpG transition temperature, depot dissolution kinetics, and retention of CpG within the depot. Mixtures of ELP‐Lys 12 , excipient ELP, and CpG undergo microphase separation, forming a porous, sponge‐like depot that contains tunable amounts of soluble CpG in the pores. In vivo, the modified formulations exhibit varying degrees of CpG retention over multiple weeks following a single intratumoral injection. Finally, by modifying the release kinetics of CpG, optimized ELP‐CpG achieves greater reduction of metastatic disease in a murine metastatic breast cancer model than soluble CpG. These results demonstrate that ELPs can be used to precisely tune the release kinetics of immunotherapies for better outcomes in the treatment of metastatic cancer.